Updated:
University Hospitals Ventures
UH Ventures is the innovation and commercialization arm of University Hospitals, led by David Sylvan.
University Hospitals Ventures
UH Ventures was established as the innovation and commercialization arm of University Hospitals, a comprehensive health system based in Cleveland, Ohio. David Sylvan, who also serves as Chief Strategy, Innovation & Marketing Officer for the system, leads the unit. The wealth origin is the operating revenue of University Hospitals itself. The strategy spans inside-out (commercializing UH-developed inventions) and outside-in (sourcing external solutions). The team covers digital health, medical devices, advanced analytics, and care delivery models. It uses direct investments, joint ventures, and co-development partnerships. Confirmed portfolio companies are not publicly listed on the site, but the team has evaluated and supported technologies across performance nutrition, biomechanics, surgical tech, and more (per the firm). Geographic focus is primarily Northeast Ohio, with broader US and international reach through partnerships. The team numbers about 19 professionals plus executives in residence and an advisory council. Adjacent vehicles include the UH Haslam Sports Innovation Center and the Feuer Innovation Accelerator. In 2024, Becker's Healthcare recognized University Hospitals as one of 51 hospital systems with great innovation programs. The structural differentiator is that UH Ventures is embedded within a large health system — it has direct access to clinical needs, patient populations, and operational data that external VCs lack. This inside-out pipeline, combined with a dedicated investment team, gives it a unique position between a corporate venture arm and a traditional healthcare VC.
General information
Firm type
other
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Cleveland
Corporate office
Cleveland, OH, United States
Principals
David Sylvan
President, UH Ventures; Chief Strategy, Innovation & Marketing Officer, University Hospitals
Neil Wyant
Vice President and Managing Director
Matthew Zenker
Director of Deal Flow and Investment
Kipum Lee
Head of UH Ventures
Sector focus
Frequently asked questions
Who leads investment decisions at UH Ventures?
David Sylvan is President of UH Ventures and also the Chief Strategy, Innovation & Marketing Officer for University Hospitals. The investment team includes Neil Wyant (Vice President and Managing Director) and Matthew Zenker (Director of Deal Flow and Investment), who oversee deal sourcing and diligence (per the firm's website).
Is UH Ventures structured as a standalone venture firm or a corporate innovation arm?
UH Ventures is the innovation and commercialization arm of University Hospitals, a $6B health system. It operates as an internal unit, not as a separate legal entity. Its activities include technology transfer, product development, direct investments, joint ventures, and partnerships — all aligned with the health system's strategic priorities (per the firm's website).
Does UH Ventures only invest in companies founded by University Hospitals employees?
No, UH Ventures pursues both inside-out and outside-in strategies. The inside-out pipeline commercializes inventions from UH caregivers. The outside-in team sources external technologies and startups that can address system needs. The team evaluates opportunities from anywhere, though priority goes to solutions that improve patient care or operational efficiency at UH (per the firm's website).
What investment stages does UH Ventures target?
UH Ventures focuses on early-stage technologies, from invention disclosure and proof-of-concept to pilot and commercialization. It uses direct investments, joint ventures, and co-development. The team also manages a grant program (the C-Path Translational Therapeutics Accelerator example) and works with external partners to fund later-stage opportunities (per the firm's website).
Does UH Ventures have a dedicated investment fund with disclosed AUM?
UH Ventures does not publicly disclose an AUM or a dedicated fund size. Its investment activities are integrated into the overall University Hospitals budget and strategy. The team deploys capital through direct investments, joint ventures, and partnerships, but no separate fund or AUM figure is published (per the firm's website).
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: